Risk Partners Life Sciences Roundtable 2024, thank you very much! Already for the 26.06.2025 >

The revolution in D&O insurance
in Nevada has now been called off after all.

In the US market, the state of Nevada passed an interesting law in the summer (Bill No. 398) with potentially significant implications for the D&O insurance market. The Governor of Nevada approved the bill on June 3, 2023, so the law came into force on October 1, 2023. We had classified this legislation (in the USA, insurance supervision is organized at state level) as something to watch for our clients, but can now probably cross this law off our "to watch list" for the time being. What has happened now?

Review: The law generally prohibited insurers from renewing or renewing any policy where the defense costs of a claim or lawsuit were deducted from the sum insured. The intention of the legislator was to leave the sum insured untouched for the indemnification. However, in many parts of the world - including Germany - offsetting is a common procedure in the event of a claim, for example under a D&O insurance policy. A lot of data is now available in the USA - especially for listed companies - including data on expenses for defense costs, but it would still have posed major challenges for insurers in terms of their capacity planning per risk. There would probably have been considerable uncertainty, which would have resulted in reduced sums insured and/or significantly higher premiums. Initially in Nevada and possibly also in other states, if not across the whole of the USA and therefore probably also for UK/European capacities for US-listed risks and local US subsidiaries.

The uncertainty surrounding the law led to an emergency order on July 20, 2023 to clarify the applicability of the law. The Nevada Division of Insurance ultimately responded to feedback and concerns from the insurance industry. Executive Order R029-23 specified the types of liability insurance policies to which the law applies. These are:

  1. Insurance cover against legal liability arising from the ownership or operation of a motor vehicle;
  2. Insurance cover against legal liability arising from the possession of owner-occupied residential property;
  3. for public liability insurance;
  4. for commercial motor vehicle insurance; or
  5. Insurance cover for the professional liability of certain healthcare providers.

 

The regulation also clarifies that the law does not apply to:

  1. "Risk retention groups" ("risk collectives");
  2. Captive insurance policies that do not cover third-party liability; or
  3. insurers that are not authorized to transact insurance business in Nevada but are authorized under applicable law to provide certain insurance coverage in Nevada that cannot be procured from authorized insurers.

 

Executive Order R029-23 went into effect on October 1, 2023 to mirror the effective date of Act No. 398. As can be seen from the points above, D&O insurers in Nevada can now breathe a sigh of relief as they are not (or no longer) affected by the law. We also no longer expect any impact on the US D&O insurance market as a result of the law in Nevada and therefore also not on the UK/European market for US-listed companies. The traditional understanding of the sum insured/SIR therefore remains unchanged.

Also read our other blog posts

Life Sciences

Cyber Risks: Case Study Evotec

Last year, more than 10 percent of German companies were affected by an IT security incident, with the proportion rising due to cyber attacks. Biotechnology is not excluded either. It is possible to learn from the Evotec case. It is about successful cyber attacks or other incidents that are important for security, such as acts of sabotage or hardware theft. According to a representative Ipsos survey conducted on behalf of the TÜV association among 501 companies with more than ten employees. According to the TÜV

Read more "
Life Sciences

St. Gallen study: USD 6 billion per drug

HSG St. Gallen: Drug costs USD 6.16 billion on average. Are the days of new drugs costing less than USD 1 billion over? There were figures in the industry that spoke of USD 700-1,000 million as the cost of developing a new drug. A study by the University of St. Gallen covering the period 2001-2020 found that the cost of developing new drugs has risen dramatically. It was estimated that the cost of developing a new drug now stands at

Read more "